Treatment of malignant scala posterior brain tumors in children: the chemotherapy of relapsed medulloblastoma with a dibromdulcitol containing drug regime and pharmacokinetic studies of dibromdulcitol in children.

Abstract

Dibromdulcitol (Elobromol) has favorable pharmacokinetic parameters for the treatment of brain tumors: high spinal fluid/plasma ratio and long half-life in spinal fluid. Oral application makes its administration easy. The drug combination vincristine, procarbazine, and dibromdulcitol proved to be effective in a pilot trial on relapsed medulloblastomas: 8 complete and 4 partial remissions were achieved from 16 cases. The main side effect was granulocytopenia, which was in some cases severe. However, in the dose-schedule we used it did not delay the treatment longer than 1 week.

• Authors: D Schuler, P Somló, R Koóos, R Kálmánchey, E Paraicz
• Journal: Medical and pediatric oncology (Med Pediatr Oncol) Vol. 20 Issue 4 Pg. 312-4 ( 1992) ISSN: 0098-1532 [Print] United States
• PMID: 1608353 (Publication Type: Journal Article)

Chemical References

• Procarbazine
• Vincristine
• Mitolactol

Topics

• Adolescent
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cerebellar Neoplasms (diagnostic imaging, drug therapy, metabolism)
• Child
• Child, Preschool
• Female
• Humans
• Male
• Medulloblastoma (diagnostic imaging, drug therapy, metabolism)
• Mitolactol (administration & dosage, pharmacokinetics)
• Neoplasm Recurrence, Local (drug therapy)
• Procarbazine (administration & dosage)
• Remission Induction
• Tomography, X-Ray Computed
• Vincristine (administration & dosage)